Special Project Grant Awarded to DMG-ACT Group at PNOC

The DMG-ACT (Diffuse Midline Glioma - Adaptive Combinatorial Therapy) initiative is a collaborative research effort aimed at accelerating the development of effective treatments for diffuse midline gliomas (DMGs), including DIPG. It involves a large, international group of researchers, clinicians, and organizations focused on improving outcomes for patients with these aggressive and hard-to-treat brain tumors.

The core of DMG-ACT's approach is to use adaptive combinatorial therapy, which involves testing combinations of therapies, including drugs and targeted treatments, in a more flexible and responsive way than traditional clinical trials. The initiative seeks to find effective combinations of therapies tailored to the specific biology of each patient’s tumor, with the goal of overcoming treatment resistance and improving survival rates.

DMG-ACT emphasizes collaboration between leading institutions, sharing data and findings to accelerate discovery, and applying the latest in scientific advancements, including personalized medicine and genomic profiling, to better understand and treat these cancers.